Dr. Hamilton on FDA Approval of Adjuvant Pertuzumab Regimen in HER2+ Early Breast Cancer

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

Related Content:

Sarah Cannon Research InstituteOncLive TVBreast CancerHER2+ Breast Cancer
Key Considerations When Ordering Biomarker Testing
Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer
Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma